Fungal infections in patients undergoing blood and marrow transplantation

Transplant Infectious Disease

Volumn 1, Issue 4, 1999, Pages 237-246

  Marr, K A ^a,b   Bowden, R A ^b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Providence Seattle Medical Center   (United States)

Author keywords

Blood and marrow transplant infections; Fungal infection; Mycoses

Indexed keywords

ANTIFUNGAL AGENT;

ALLOTRANSPLANTATION; ASPERGILLOSIS; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CANDIDIASIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MYCOSIS; REVIEW;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CANDIDIASIS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; INCIDENCE; MYCOSES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033302161     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.1999.010403.x     Document Type: Article

References (74)

1. MEIS J, RUHNKE M, DEPAUW B, ODDS F, SIEGERT W, VERWEIJ P. Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerging Infect Dis 1999: 5: 150-153.
2. WINGARD JR. Importance of Candida species other than C albicans as pathogens in oncology patients. Clin Infect Dis 1995: 20: 115-125.
3. BORG M, RUCHEL R. Demonstration of fungal proteinase during phagocytosis of Candida albicans and Candida tropicalis. J Med Vet Mycol 1990: 28: 3-14.
4. CORNER BE, MAGEE PT. Candida pathogenesis: Unravelling the threads of infection. Curr Biol 1997: 7: R691-R694.
5. WINGARD JR, MERZ WG, RINALDI MG, JOHNSON TR, KARP JE, SARAL R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Eng J Med 1991: 325: 1274-1277.
6. WINGARD JR, MERZ WG, RINALDI MG, MILLER CB, KARP JE, SARAL R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993: 37: 1847-1849.
7. MARR KA, SEIDEL K, WHITE TC, BOWDEN RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 1999: (in press).
8. VISCOLI C, GIRMENIA C, MARKUS A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999: 28: 1071-1079.
9. DENNING DW. Invasive aspergillosis. Clin Infect Dis 1998: 26: 781-805.
10. LATGE J. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999: 12: 310-350.
11. DENNING DW, VENKATESWARLU K, OAKLEY KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997: 41: 1364-1368.
12. PERFECT J, SCHELL W. The new fungal opportunists are coming. Clin Infect Dis 1996: 22 (Suppl 2): S112-S118.
13. ABI SAID D, ANAISSIE E, UZUN O, RAAD I, PINZCOWSKI H, VARTIVARIAN S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997: 24: 1122-1128.
14. VAN BURK JH, LEISENRING W, MYERSON D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. Medicine 1998: 77: 246-254.
15. DRAKOS P, NAGLER A, OR R, et al. Invasive fungal sinusitis in patients undergoing bone marrow transplantation. Bone Marrow Transpl 1993: 12: 203-208.
16. MAURY S, LEBLANC T, FEUILHADE M, MOLINA J, SCHAISON G. Successful treatment of disseminated mucormycosis with liposomal amphotericin B and surgery in a child with leukemia. Clin Infect Dis 1998: 26: 200-202.
17. DEMEDEIROS C, CUNHA ADD, PASQUINI R, ARNS DA CUNHA C. Primary renal aspergillosis: extremely uncommon presentation in patients treated with bone marrow transplantation. Bone Marrow Transpl 1999: 24: 113-114.
18. MCWHINNEY P, KIBBLER C, HAMON M, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993: 17: 397-404.
19. WILLIAMSON E, MILLAR M, STEWARD C, et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999: 104: 560-568.
20. WALD A, LEISENRING W, VAN BURIK J, BOWDEN RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997: 175: 1459-1466.
21. JANTUNEN E, RUUTU P, NISKANEN L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997: 19: 801-808.
22. SAUGIER-VEBER P, DEVERGIE A, SULAHIAN A, et al. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study. Bone Marrow Transplant 1993: 12: 121-124.
23. WALSH T, CHANOCK S. Diagnosis of invasive fungal infections in transplant recipients. In: RA BOWDEN PL, CV PAYA, eds. Transplant Infections. Philadelphia: Lippincott-Raven Publishers, 1999: 79-103.
24. BROWN M, WORTHY S, FLINT J, MULLER N. Invasive aspergillosis in the immunocompromised host: utility of computed tomography and bronchoalveolar lavage. Clin Radiol 1998: 53: 255-257.
25. VERWEIJ P, STYNEN D, RIJS A, DE PAUW B, HOOGKAMP-KORSTANJE J, MEIS J. Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol 1995: 33: 1912-1914.
26. SULAHIAN A, TABOURET M, RIBAUD P, et al. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis 1996: 15: 139-145.
27. MAERTENS J, VERHAEGEN J, DEMUYNCK H, ELDERE JV, VERBIST L, BOOGAERTS M. Prospective evaluation of serum galactomannan (GM) levels measured by sandwich-ELISA technique in invasive aspergillosis. Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, 1999.
28. EINSELE H, HEBART H, ROLLER G, et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997: 35: 1353-1360.
29. YAMAKAMI Y, HASHIMOTO A, TOKIMATSU I, NASU M. PCR Detection of DNA specific for Aspergillus species in serum of patients with invasive aspergillosis. J Clin Microbiol 1996: 34: 2464-2468.
30. LOEFFLER J. Application of PCR to detect fungi in clinical samples. Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, 1999.
31. VANBURIK J, MYERSON D, SCHRECKHISE R, BOWDEN R. Panfungal PCR assay for detection of fungal infection in human blood samples. J Clin Microbiol 1998: 36: 1169-1175.
32. BRETAGNE S, COSTA J, MARMORAT-KHOUNG A, et al. Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR. J Clin Microbiol 1995: 33: 1164-1168.
33. ASCIOGLU A, DEPAUW B, BENNETT J, et al. Analysis of definitions used in clinical research on invasive fungal infections (IFI): consensus proposal for new, standardized definitions. Interscience Conference on Antimicrob Agents and Chemotherapy; San Francisco, CA, 1999.
34. WALSH T, FINBERG R, ARNDT C, et al. Liposomal amphotericin B for empiric therapy in patients with persistent fever and neutropenia. N Engl J Med 1999: 340: 764-771.
35. WINGARD J, WHITE M, ANAISSIE E, et al. A randomized double-blind comparative safety trial of AmBisome and Abelcet in febrile neutropenia patients. Focus on Fungal Infection; San Diego, CA, 1999.
36. FLEMING R, KANTARJIAN H, HUSNI R, et al. Randomized study of two lipid formulations of amphotericin B in the treatment of suspected or documented fungal infection in patients with leukemia. Focus on Fungal Infection; San Diego, CA, 1999.
37. EDWARDS JE, BODEY GP, BOWOEN RA, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997: 25: 43-59.
38. MARR KA, WHITE TC, VAN BURIK JAH, BOWDEN RA. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997: 25: 908-910.
39. NOLTE FS, PARKINSON T, FALCONER DJ, et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997: 41: 196-199.
40. SPITZER G, ADKINS D, SPENCER V, et al. Randomized study of growth factors post PBSC transplant. Neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1995: 13: 1323.
41. NEUMUNAITIS J, ROSENFELD C, ASH R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF in allogeneic bone marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Bone Marrow Transplant 1995: 15: 949.
42. KHAJA A, LINCH D, GOLDSTONE A, et al. rhG-CSF after bone marrow transplantation for malignant lymphoma: a BNLI double-blind placebo-controlled trial. Br J Haematol 1992: 82: 317.
43. ANASETTI C, ANDERSON G, APPELBAUM F, et al. Phase-III study of rh-GM-CSF in allogeneic bone marrow transplantation from unrelated donors. Blood 1993: 82: 454a.
44. ANAISSIE E, REX J, UZUN O, VARTIVARIAN S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998: 104: 238-245.
45. RIBAUD P, CHASTANG C, LATGE J, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999: 28: 322-330.
46. DENNING DW. Therapeutic outcome of invasive aspergillosis. Clin Infect Dis 1996: 23: 608-615.
47. PANNUTI C, GINGRICH R, PFALLER M, et al. Nosocomial pneumonia in patients having bone marrow transplantation. Cancer 1991: 69: 2653-2662.
48. WHITE M, ANAISSIE E, KUSNE S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997: 24: 635-642.
49. WALSH T, HIEMENZ J, SEIBEL N, et al. Amphoterin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998: 26: 1383-1396.
50. ELLIS M, SPENCE D, PAUW BD, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998: 27: 406-412.
51. BOWDEN R, CHANDRASEKAK P, WHITE M, BURIK JV, WINGARD J. A double-blind, randomized controlled trial of amphocil (ABCD) vs. amphotericin B (AmB) for treatment of invasive aspergillosis in immunocompromised patients. Tenth International Symposium on Infection in the Immunocompromised Host; Davos, Switzerland; 1998.
52. ROILIDES E, BLAKE C, HOLMES A, PIZZO P, WALSH T. Granulocyte-macrophage colony-stimulating factor and interferon-γ prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996: 34: 63-69.
53. ROILIDES E, SEIN T, HOLMES A, et al. Effects of macrophage colony-stimulating factor on antifungal activity on mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis 1995: 172: 1028-1034.
54. CAILLOT D, CASASNOVAS O, BERNARD A, et al. Improved management of invasive aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997: 15: 139-147.
55. DENNING D, STEVENS D. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990: 12: 1147-1201.
56. MARTINO R, NOMDEDEU J, SUREDA A, BRUNET S, MARTINEZ C, DOMINO-ALBOS A. Successful bone marrow transplantation in patients with previous fungal infections: report of four cases. Bone Marrow Transplant 1994: 13: 265-273.
57. ROBINSON L, REED E, GALBRAITH T, ALONSO A, MOULTON A, FLEMLNG W. Pulmonary resection for invasive Aspergillus infections in immunocompromised patients. J Thorac Cardiovasc Surg 1995: 109: 1182-1197.
58. OFFNER F, CORDONNIER C, LJUNGMAN P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998: 26: 1098-1103.
59. SLAVIN MA, OSBORNE B, ADAMS R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. J Infect Dis 1995: 171: 1545-1552.
60. GOODMAN JL, WINSTON DJ, GREENFIELD RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992: 326: 845-831.
61. GUBBINS PO, BOWMAN JL, PENZAK SR. Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplant recipients. Pharmacother 1998: 18: 549-564.
62. LORTHOLARY O, DUPONT B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev 1997: 10: 477.
63. CASTAGNOLA E, BUCCI B, MONTINARO E, VISCOLI C. Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol. Bone Marrow Transplant 1996: 18 (Suppl 2): 97-106.
64. HANSEN JA, GOOLEY TA, MARTIN PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998: 338: 962-968.
65. PERFECT J, KLOTMAN M, GILBERT C, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992: 165: 891-897.
66. O'DONNELL M, SCHMIDT G, TEGTMEIER B, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994: 12: 827-834.
67. ROUSEY S, RUSSLER S, GOTTLEIB M, ASH R. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am J Med 1991: 91: 484-492.
68. TOLLEMAR J, RINGDEN O, ANDERSSON S, SUNDBERG B, LJUNGMAN P, TYDEN G. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow tranpslant recipients. Bone Marrow Transplant 1993: 12: 577-582.
69. SCHWARTZ S, BEHRE G, HEINEMANN V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999: 93: 3654-3661,
70. ANAISSIE E, STRATTON S, SUMMERBELL R, MONSON T, REX J, WALSH T. Aspergillus species aerosols in hospitals: showering as a potential mode of exposure. Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, 1999.
71. WARRIS A, GAUSTAD P, MEIS J, VERWEIJ P, ABRAHAMSEN T. Water as a source of filamentous fungi in a childhood bone marrow transplantation unit. Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, 1999.
72. GOODRICH JM, REED C, MORI M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991: 164: 731-740.
73. SPARRELID E, HAGGLUND H, REMBERGER M, et al. Bacteremia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998: 22: 795-800.
74. MORRISON V, HAAKE R, WEISDORF D. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1993: 96: 497-503.